Takeda: treat-to-target therapy with ENTYVIO cuts ulcerative colitis complication risk
Takeda says Phase 4 VERDICT data show ENTYVIO's treat-to-target strategy prolonged time to first ulcerative colitis complication, with HR 0.33 and consistent safety.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Takeda Pharmaceutical, according to TradingView, has presented Phase 4 results from the VERDICT study of its drug ENTYVIO. A treat-to-target approach aimed at full clinical clearance extended the time to the first ulcerative colitis-related complication, compared with symptomatic remission alone. The hazard ratio was 0.33 (95% CI 0.17 to 0.67; P=0.0014). 57% of patients reached clearance by Week 16, and the safety profile remained consistent with earlier data through 96 weeks.
why it matters
For Takeda, the data mainly reinforce ENTYVIO's position in moderate-to-severe ulcerative colitis rather than shift the outlook sharply. Guideline updates, payer coverage changes or label revisions reflecting treat-to-target clearance would be bigger catalysts for the shares.
tags
instruments
sources
- Takeda Pharmaceutical Company Limited Says ENTYVIO Treat-to-Target Cut UC Complication Risk ~70% — TradingView, 19 October 2026 at 09:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗